BioSpace News Archive

Deals

Invitation to MorphoSys Q2 2019 Conference Call on August 7, 2019

MorphoSys AG will publish its first six months’ 2019 results on August 6, 2019 at 10:00pm CEST.

July 25, 2019
·
4 min read
Deals

Sofinnova Partners Sells Breath Therapeutics to Italian Pharma Company

The sale of Germany-based Breath comes after the company launched two late-stage trials assessing its lead product as a treatment for a disease that affects lung transplant patients.

July 25, 2019
·
3 min read
·
Alex Keown
Genetown

Sage Therapeutics Updates Pipeline to Focus on Treatment-Resistant Depression

The company is working to break into the broader depression market with SAGE-217. The company discussed its pipeline at its “FutureCast.”

July 25, 2019
·
3 min read
·
Mark Terry
Drug Development

CelGro® pre-clinical study validates high quality nerve repair

CelGro® Human Nerve Regeneration Trial Recently Orthocell announced that the first four patients successfully completed participation in the CelGro® nerve regeneration clinical trial.

July 25, 2019
·
6 min read
Deals

Gimv and other shareholders sell biopharmaceutical company Breath Therapeutics to Zambon after a fast development

Gimv, Sofinnova and Gilde Healthcare announced the sale of biopharmaceutical company Breath Therapeutics.

July 25, 2019
·
4 min read
Drug Development

Evotec SE: Positive Phase II data for P2X3 antagonist in patients with refractory chronic cough

Evotec SE announced that the Company has been informed by Bayer about positive Phase IIa results from a study surveying the safety, efficacy and dosage of the compound BAY1817080 in refractory chronic cough.

July 25, 2019
·
1 min read
Business

Strong clinical progress in H1 and transformative collaboration with Gilead announced

Galapagos NV announces its unaudited first half-year results, which are further detailed in its H1 2019 report available on the Galapagos website, www.glpg.com.

July 25, 2019
·
8 min read
Drug Development

Bristol Myers’ CheckMate-227 Trial Shows Mixed Results for NSCLC Patients

A combination of Opdivo and Yervoy hit the primary endpoint in NSCLC patients with PD-L1 expression. Opdivo and chemotherapy did not demonstrate efficacy in patients regardless of PD-L1 expression.

July 25, 2019
·
2 min read
·
Alex Keown
Lone Star Bio

PARP Inhibitors Can Play Larger Role in Treating Cancer Patients, Study Finds

Researchers from UT Southwestern discovered that PARP inhibitors can also impact the cellular production of ribosomes, a protein cancer cells depend upon.

July 25, 2019
·
3 min read
·
Alex Keown
Business

BioSpace Movers and Shakers, July 26

Biotech and pharma companies bolster their executive leadership and boards of directors with this week’s appointments.

July 25, 2019
·
8 min read
·
Alex Keown